Table 3.
Metabolic and inflammatory markers of individuals with prediabetic subject to supplementation with 200, 400, or 800 mg/day for 12 weeks
| Variables | Period | Eriomin | |||
|---|---|---|---|---|---|
| Week | Placebo | 200 mg | 400 mg | 800 mg | |
| Glucagon (pg/ml) | 0 | 143 ± 19 | 144 ± 23a | 142 ± 19a | 143 ± 14a |
| 12 | 142 ± 20A | 134 ± 21b, B | 135 ± 19b, B | 132 ± 14b, B | |
| δ (12–0 week) | −0.7% a | −6.9% a | −4.9% a | −7.7% a | |
| −6.5% b | |||||
| C‐peptide (pg/ml) | 0 | 2122 ± 636 | 2172 ± 727a | 2163 ± 767a | 2151 ± 624a |
| 12 | 2106 ± 675A | 2047 ± 613b, B | 2055 ± 803b, B | 2046 ± 648b, B | |
| δ (12–0 week) | −0.8% | −5.8% | −5.0% | −4.9% | |
| −5.2% | |||||
| GLP‐1 (rmol/L) | 0 | 8.48 ± 1.96 | 8.52 ± 2.72a | 8.55 ± 2.75a | 8.57 ± 2.11a |
| 12 | 8.50 ± 1.96A | 9.85 ± 2.68b, B | 9.80 ± 1.95b, B | 9.89 ± 2.15b, B | |
| δ (12–0 week) | 0.2% | 15.6% | 14.6% | 15.4% | |
| 15.2% | |||||
| hsCRP (mg/dl) | 0 | 0.43 ± 0.36 | 0.44 ± 0.33a | 0.42 ± 0.30a | 0.41 ± 0.42a |
| 12 | 0.43 ± 0.41A | 0.38 ± 0.25b, B | 0.39 ± 0.34b, B | 0.35 ± 0.30b, B | |
| δ (12–0 week) | 0.0% | −13.6% | −7.1% | −14.6% | |
| −11.8% | |||||
| IL‐6 (pg/ml) | 0 | 6.84 ± 4.33 | 6.83 ± 3.12a | 6.82 ± 4.43a | 6.83 ± 4.92a |
| 12 | 6.82 ± 4.61A | 5.89 ± 2.23b, B | 5.84 ± 3.04b, B | 6.03 ± 3.80b, B | |
| δ (12–0 week) | −0.3% | −13.8% | −14.4% | −11.7% | |
| −13.3% | |||||
| TNF‐α (pg/ml) | 0 | 5.64 ± 1.73 | 5.66 ± 1.91a | 5.67 ± 1.88a | 5.65 ± 1.79a |
| 12 | 5.63 ± 2.03A | 4.98 ± 1.59b, B | 5.06 ± 1.63b, B | 5.02 ± 1.96b, B | |
| δ (12–0 week) | −0.2% | −12.0% | −10.8% | −11.2% | |
| −11.3% | |||||
| Adiponectin (μg/ml) | 0 | 18.4 ± 5.6 | 18.7 ± 5.7a | 17.9 ± 7.5a | 18.1 ± 7.6a |
| 12 | 18.7 ± 5.3A | 22.2 ± 6.6b, B | 21.8 ± 8.9b, B | 21.1 ± 6.6b, B | |
| δ (12–0 wk) | 1.6% | 18.7% | 21.8% | 16.6% | |
| 19.0% | |||||
| Lipid peroxidation (MDA; mM) | 0 | 1.77 ± 0.91 | 1.77 ± 0.58a | 1.78 ± 0.67a | 1.77 ± 0.82a |
| 12 | 1.76 ± 0.94A | 1.33 ± 0.67b, B | 1.53 ± 0.86b, B | 1.54 ± 0.84b, B | |
| δ (12–0 week) | −0.6% | −24.9% | −14.0% | −13.0% | |
| −17.3% | |||||
| Antioxidant capacity (μM) | 0 | 1.87 ± 0.03 | 1.88 ± 0.09a | 1.88 ± 0.03a | 1.87 ± 0.09a |
| 12 | 1.88 ± 0.03A | 1.99 ± 0.04b, B | 1.99 ± 0.03b, B | 1.98 ± 0.03b, B | |
| δ (12–0 week) | 0.5% | 5.9% | 5.9% | 5.3% | |
| 5.7% | |||||
Note. Two‐way repeated measures ANOVA followed by Sidak test among groups (placebo, 200, 400, and 800 mg) over 12‐week intervention period; p ≤ .05. Different letters (a, b) indicate difference within the group, and different uppercase letters (A, B) indicate difference between groups.
a
Difference between week 12 and 0.
b
Mean of the percentage differences between the groups supplemented with Eriomin.